Please login to the form below

Not currently logged in
Email:
Password:

patent challenge

This page shows the latest patent challenge news and features for those working in and with pharma, biotech and healthcare.

First blood to Roche in Hemlibra patent fight with Shire

First blood to Roche in Hemlibra patent fight with Shire

First blood to Roche in Hemlibra patent fight with Shire. The new haemophilia drug does not infringe Baxalta’s patent, rules Tokyo court. ... Roche’s defence of its haemophilia drug Hemlibra against a patent infringement challenge by Shire has been

Latest news

  • Shire claims FDA approval for slow-cooked ADHD drug Shire claims FDA approval for slow-cooked ADHD drug

    Either way the new drug is a boost to Shire's ADHD franchise now that Adderall XR and Intuniv (guanfacine) have lost patent protection in most major markets, and along with ... Vyvanse remains under patent challenge from would-be generic rivals, but so

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    The US patent for the oral formulation expires this year, but the injectable remains protected until 2019, according to Merck. ... In the meantime Merck is also facing a challenge on its injectable patent from Apotex, which filed a petition with the US

  • China turns down one of two Sovaldi patents China turns down one of two Sovaldi patents

    The challenge to the Chinese patent was filed by the Initiative for Medicines, Access &Knowledge (I-MAK), an advocacy group that is trying to overturn Gilead's intellectual property for Sovaldi ... that are currently reviewing patent applications for the

  • German court overturns patent on Lilly blockbuster Alimta German court overturns patent on Lilly blockbuster Alimta

    The patent challenge was not for the compound patent on pemetrexed disodium - the active ingredient in Alimta - but for a vitamin regimen used alongside the drug that is designed to limit ... The German Court of Appeal upheld a challenge by Actavis of

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    In addition to quicker review times, QIDP status also gives an extra five years of patent life for the antibiotic product. ... patent challenge filed in a US court by generic drugmaker Hospira.

More from news
Approximately 1 fully matching, plus 52 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Indians scalp cowboys in patent war

    Indians scalp cowboys in patent war. An unlikely treaty between global pharma and native Americans. ... claims? You can expect lawyers working for generics manufacturers to vigorously challenge the Allergan strategy.

  • Indians scalp cowboys in patent war

    Indians scalp cowboys in patent war. An unlikely treaty between global pharma and native Americans. ... claims? You can expect lawyers working for generics manufacturers to vigorously challenge the Allergan strategy.

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics